Key statistics
Previous close$26.64
Open$25.99
Day high$27.84
Day low$25.68
52-week high$31.74
52-week low$8.84
Market cap2.76B
Volume781.58K
Average volume1.33M
P/E ratio-8.41
Forward P/E—
EPS-3.26
Dividend yield0.00%
Market context
Why it moved
RCUS (Arcus Biosciences) shares moved higher, supported by renewed investor interest and analyst coverage highlighted in a report offering insights on the company, while the stock also appeared on 52-week gainer rankings, reflecting continued positive momentum in the healthcare/biotech sector.
What is happening
Recent company-specific developments and publisher coverage.
July 17, 2026Arcus Biosciences tumbled nearly 5%, pulling back from recent highs as insider selling weighed on sentiment — co-founder and President Juan C. Jaen sold 68,569 shares for ~$2.03 million on July 9–10 under a Rule 10b5-1 plan, just below the stock's 52-week high of $31.73 following a 201% run over the past year. The decline came despite Truist Securities initiating coverage with a Buy rating and a $35 price target, citing casdatifan's best-in-class potential in renal cell carcinoma, while the broader healthcare sector (XLV) held relatively steady and the S&P 500 dipped modestly amid tech-driven selling pressure.-4.9251
July 15, 2026Arcus Biosciences closed modestly lower, weighed by continued investor scrutiny following Co-Founder and President Juan C. Jaen's sale of 68,569 shares (~$2.03M) under a Rule 10b5-1 plan at prices between $28.61–$30.05 — near the stock's 52-week high of $31.73 after a ~201% one-year run. While the planned nature of the sale limits its signal, it arrives alongside a Q1 earnings miss (EPS of -$1.02 vs. -$0.85 expected) and an InvestingPro overvaluation flag, tempering sentiment even as Truist Securities recently initiated coverage with a Buy rating and $35 target, citing casdatifan's promising profile in renal cell carcinoma.-1.0942
July 14, 2026Arcus Biosciences edged higher as investors weighed a notable insider sale disclosure against continued pipeline optimism. President Juan C. Jaen sold 68,569 shares (~$2.03M) under a pre-arranged Rule 10b5-1 plan at prices between $28.61–$30.05, though he retained over 1.2 million shares. Bullish sentiment around lead candidate casdatifan in renal cell carcinoma persists, supported by a recent Nature publication and Truist Securities' Buy rating with a $35 price target, even as Q1 results missed estimates and the broader healthcare sector faces headwinds.0.9263
July 14, 2026Arcus Biosciences fell amid a confluence of company-specific and macro headwinds, with the stock still digesting Gilead Sciences' recent decision to walk away from its partnership — a significant blow given Gilead's deep financial and strategic ties to the company. Adding to the pressure, president Juan C. Jaen sold approximately $2 million in shares under a pre-arranged 10b5-1 plan, a visible insider transaction that drew investor attention. Broader market sentiment was also negative, with U.S. equities declining as renewed U.S.-Iran military tensions sent oil prices surging and weighed on risk appetite.-2.9391
July 8, 2026Arcus Biosciences edged higher and extended gains in after-hours trading, buoyed by continued investor enthusiasm following Nature's publication of ARC-20 study data linking deeper HIF-2α inhibition with improved outcomes in metastatic kidney cancer — a catalyst that has driven a ~31% 30-day price surge. The biomarker-linked efficacy signal for casdatifan has reinforced the company's late-stage RCC narrative, with analysts estimating a fair value of ~$35.75 — roughly 18% above current levels — while a June 2026 collaboration with Bristol Myers Squibb to add casdatifan to the ROSETTA RCC-208 trial adds further strategic credibility. Broader sector tailwinds, including Jim Cramer calling biotech "the hottest group in the market" amid a more favorable M&A environment, are supporting sentiment.0.9006
July 6, 2026Arcus Biosciences edged lower in regular trading but is recovering in after-hours, as investors continue to digest the Nature-published ARC-20 study data for casdatifan, its HIF-2α inhibitor for metastatic renal cell carcinoma. The publication, which links deeper serum EPO suppression to higher response rates and longer progression-free survival, has reignited valuation debate — with fair value estimates around $35.75 suggesting ~18% upside — while a June 2026 collaboration with Bristol Myers Squibb to incorporate casdatifan into the ROSETTA RCC-208 trial underscores growing partner confidence in the program. Broader healthcare sector weakness weighed on the stock during the session.-1.154
July 3, 2026Arcus Biosciences surged nearly 5% as investors responded to a landmark Nature publication validating the company's lead kidney cancer drug casdatifan. The study, drawn from the ARC-20 trial, demonstrated a compelling link between HIF-2α inhibition, serum EPO suppression, and clinical outcomes — with a pooled analysis of 121 patients showing a median progression-free survival of 12.2 months despite heavy prior treatment. The results reinforce casdatifan's best-in-class profile heading into the Phase 3 PEAK-1 study, bolstering Wall Street's constructive stance with analyst consensus price targets around $35.75. Healthcare was also the top-performing S&P sector on the day, providing a tailwind.4.8755
July 2, 2026Arcus Biosciences shares tumbled after the stock pulled back from near 52-week highs, even as the company announced a high-profile Nature publication validating casdatifan's clinical profile in kidney cancer, showing a 12.2-month median progression-free survival in a heavily pre-treated metastatic ccRCC population. The sell-off — on above-average volume — appears to reflect a classic 'sell the news' dynamic following the stock's 269% run over the past year, compounded by a broader tech- and chip-led market decline on July 1 and lingering concern over Arcus's Q1 miss. In after-hours trade, shares edged slightly off the session lows as investors digested the casdatifan data alongside a new Truist buy rating with a $35 price target.-6.1953
Simply Wall Street · July 5, 2026Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus↗Simply Wall Street · July 3, 2026How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data↗BioSpace · April 21, 2026Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls↗Seeking Alpha · March 3, 2026Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS)↗Investor's Business Daily · December 12, 2025Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak↗BioPharma Dive · December 12, 2025Arcus cancels work on Gilead-partnered cancer combo after trial setback↗ Mt Newswire · July 13, 2026Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC FilingBenzinga · July 1, 2026Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney CancerMt Newswire · June 24, 2026Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC FilingMt Newswire · June 3, 2026Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer TreatmentBenzinga · June 3, 2026Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a InhibitorBenzinga · May 18, 2026Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35Benzinga · May 11, 2026Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22Benzinga · May 7, 2026Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34
